



## Exelixis Announces Webcast of January 15 Presentation at the J.P. Morgan 32nd Annual Healthcare Conference

December 17, 2013

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Dec. 17, 2013-- Exelixis, Inc. (NASDAQ:EXEL) today announced that Michael M. Morrissey, Ph.D., the company's president and chief executive officer, will present at the J.P. Morgan 32<sup>nd</sup> Annual Healthcare Conference at 5:00 p.m. EST / 2:00 p.m. PST on Wednesday, January 15, 2014, in San Francisco. During the presentation, Dr. Morrissey will review the company's development plans and priorities for cabozantinib in 2014. He will also discuss the company's corporate strategy and financial outlook, and provide a general business update.

The presentation will be webcast and may be accessed via the Event Calendar page under Investors & Media at [www.exelixis.com](http://www.exelixis.com).

### About Exelixis

Exelixis, Inc. is a biotechnology company committed to developing small molecule therapies for the treatment of cancer. Exelixis is focusing its proprietary resources and development efforts exclusively on COMETRIQ® (cabozantinib). Exelixis has also established a portfolio of other novel compounds that it believes have the potential to address serious unmet medical needs, many of which are being advanced by partners as part of collaborations. For more information, please visit the company's web site at [www.exelixis.com](http://www.exelixis.com).

*Exelixis, the Exelixis logo, and COMETRIQ are registered U.S. trademarks.*



Source: Exelixis, Inc.

Exelixis, Inc.  
Charles Butler, 650-837-7277  
Vice President,  
Investor Relations and  
Corporate Communications  
[cbutler@exelixis.com](mailto:cbutler@exelixis.com)